Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Paull

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
The New England Journal of Medicine|August 26, 1976
The histologic spectrum of Barrett's esophagusA Paull, J S Trier, M D Dalton, et al.
Rheumatology International|January 1, 1986
Aberrant lymphocyte trafficking in murine systemic lupus erythematosusL Schrieber, A D Steinberg, Y J Rosenberg, et al.
Molecules (Basel, Switzerland)|July 2, 2021
Topical Astodrimer Sodium, a Non-Toxic Polyanionic Dendrimer, Demonstrates Antiviral Activity in an Experimental Ocular Adenovirus Infection ModelEric G Romanowski, Kathleen A Yates, Jeremy R A Paull, et al.
Antimicrobial Agents and Chemotherapy|June 17, 2009
Enhancement of human immunodeficiency virus type 1 replication is not intrinsic to all polyanion-based microbicidesSecondo Sonza, Adam Johnson, David Tyssen, et al.
Viruses|August 28, 2021
Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 MiceJeremy R A Paull, Carolyn A Luscombe, Alex Castellarnau, et al.
Sexually Transmitted Diseases|October 14, 2009
Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I studyJohn O'Loughlin, Iona Y Millwood, Helen M McDonald, et al.
Plos One|February 12, 2011
A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 daysCraig R Cohen, Joelle Brown, Anna-Barbara Moscicki, et al.
Pharmaceutics|September 28, 2024
Astodrimer Sodium Nasal Spray versus Placebo in Non-Hospitalised Patients with COVID-19: A Randomised, Double-Blinded, Placebo-Controlled TrialStephen Winchester, Alex Castellarnau, Kashif Jabbar, et al.
Antiviral Research|May 19, 2021
Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitroJeremy R A Paull, Graham P Heery, Michael D Bobardt, et al.
Scientific Reports|June 17, 2022
Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trialAlex Castellarnau, Graham P Heery, Aynaz Seta, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
The New England Journal of Medicine|August 26, 1976
The histologic spectrum of Barrett's esophagusA Paull, J S Trier, M D Dalton, et al.
Rheumatology International|January 1, 1986
Aberrant lymphocyte trafficking in murine systemic lupus erythematosusL Schrieber, A D Steinberg, Y J Rosenberg, et al.
Molecules (Basel, Switzerland)|July 2, 2021
Topical Astodrimer Sodium, a Non-Toxic Polyanionic Dendrimer, Demonstrates Antiviral Activity in an Experimental Ocular Adenovirus Infection ModelEric G Romanowski, Kathleen A Yates, Jeremy R A Paull, et al.
Antimicrobial Agents and Chemotherapy|June 17, 2009
Enhancement of human immunodeficiency virus type 1 replication is not intrinsic to all polyanion-based microbicidesSecondo Sonza, Adam Johnson, David Tyssen, et al.
Viruses|August 28, 2021
Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 MiceJeremy R A Paull, Carolyn A Luscombe, Alex Castellarnau, et al.
Sexually Transmitted Diseases|October 14, 2009
Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I studyJohn O'Loughlin, Iona Y Millwood, Helen M McDonald, et al.
Plos One|February 12, 2011
A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 daysCraig R Cohen, Joelle Brown, Anna-Barbara Moscicki, et al.
Pharmaceutics|September 28, 2024
Astodrimer Sodium Nasal Spray versus Placebo in Non-Hospitalised Patients with COVID-19: A Randomised, Double-Blinded, Placebo-Controlled TrialStephen Winchester, Alex Castellarnau, Kashif Jabbar, et al.
Antiviral Research|May 19, 2021
Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitroJeremy R A Paull, Graham P Heery, Michael D Bobardt, et al.
Scientific Reports|June 17, 2022
Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trialAlex Castellarnau, Graham P Heery, Aynaz Seta, et al.
Pageof 7